Global Infertility Drug Pipeline Analysis
The market for reproductive medicine is experiencing a paradigm shift with new latest techniques being used and awareness among people increasing due to imparting knowledge about these techniques. The infertility drugs market promises significant room for growth. The market has high potential to scale up in order to meet the needs of infertile couples and also due to growth in reproductive tourism. Venture capitalists have entered the market by investing huge amounts in setting up chains of infertility clinics, which provide drugs and treatment. The most lucrative markets for infertility drugs are the emerging nations such as India, Brazil, China and Mexico, where the population is huge and there exist large pool of people being affected by lifestyle diseases, thus leading to infertility.
“Global Infertility Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of infertility. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the infertility treatment drug market based upon development process.
Following parameters for each vaccine profile in development phase are covered in “Global Infertility Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Orphan Designation by Indication, Country & Organisation
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 1
- Preclinical: 12
- Phase-I: 2
- Phase-II: 7
- Phase-III: 8
- Preregistration: 1
- Marketed: 19
1.1 Current Market Scenario
1.2 Factors Driving Infertility Drug Market
1.3 Future Opportunity
2. INFERTILITY DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Drug Profiles in Clinical Phase
3. INFERTILITY DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Drug Profiles in Clinical Phase
4. INFERTILITY DRUG CLINICAL PHASE: PHASE-I
4.1 Overview
4.2 Drug Profiles in Clinical Phase
5. INFERTILITY DRUG CLINICAL PHASE: PHASE-II
5.1 Overview
5.2 Drug Profiles in Clinical Phase
6. INFERTILITY DRUG CLINICAL PHASE: PHASE-III
6.1 Overview
6.2 Drug Profiles in Clinical Phase
7. INFERTILITY DRUG CLINICAL PHASE: PREREGISTRATION
7.1 Overview
7.2 Drug Profiles in Clinical Phase
8. MARKETED INFERTILITY DRUGS
8.1 Overview
8.2 Marketed Drug Profiles
Infertility Drug Market Overview
The market for infertility treatments offers large opportunities. Currently, the market for reproductive medicine is experiencing a paradigm shift with new latest techniques being used and awareness among people increasing due to imparting knowledge about these techniques.The infertility drugs market promises significant room for growth. The market has high potential to scale up in order to meet the needs of infertile couples and also due to growth in reproductive tourism. Venture capitalists have entered the market by investing huge amounts in setting up chains of infertility clinics, which provide drugs and treatment.
The techniques to improve fertility among couples have developed significantly and this holds many opportunities for the future. With the methods like cryopreservation of embryos, oocytes, or ovarian tissue, which are currently available in the market, the prolongation of fertility has been made feasible. It is most likely that in the future, the rejuvenation of ageing oocytes will enable ageing women to achieve pregnancy with their genetic offspring. The other alternative method for patient with poor depleted germ cells is the production of germ cells from embryonic stem cells, which is also gaining popularity. The number of pharma companies investing in this stem cell research is increasing gradually owing to the benefits that have been identified.
With a deeper understanding of the entire process of infertility, and with the development of new drugs, and surgical equipments, it is expected that the treatment would become more effective, economical and convenient, thus attracting many more companies to invest and gain benefits in the future years.
Factors Driving Infertility Drug Market
It has been estimated that approximately xx million females were seeking medical care for infertility problems across the globe. With infertility being more common, it is most likely that this figure would reach xx million by 2017.
The major drivers of growth for the infertility drugs market include increasing number of infertile people, increasing worldwide obesity and rising disposable incomes of the consumers. Among the other factors are the increasing number of smokers, an increase in the levels of stress and pollution, more adoption of babies by homosexual couples and the availability of government support for infertility abatement procedures.
The most lucrative markets for infertility drugs are the emerging nations such as India, Brazil, China and Mexico, where the population is huge and there is a high percentage of people being affected by lifestyle diseases, thus leading to infertility.
Additionally, these emerging nations are taking conscious efforts to develop and improve medical tourism, which is a further booster to the infertility drugs market. Also, the foreign tourists entering these nations get access to cheap and economical treatment, along with accepted standards of quality, which is a win-win situation for all the stakeholders in the market.
